title: [Lupus erythematosus and proto-pump inhibitors].
authors.affiliation: Service de dermatologie, CHU de Nancy, bâtiment des spécialités médicales, allée du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: jl.schmutz@chu-nancy.fr.
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
authors.affiliation: Centre de pharmacovigilance, CHU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France.
authors.forename: P
authors.initials: P
authors.lastname: Trechot
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001706:Biopsy; D003937:Diagnosis, Differential; D064098:Esomeprazole / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D011247:Pregnancy; D054328:Proton Pump Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001323:Autoantibodies; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole; D064098:Esomeprazole